Clinical Trials Logo
  1. Home
  2. Myasthenia Gravis, Generalized
  3. NCT03165435

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

Myasthenia Gravis, Generalized Clinical Trial

Official title:
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.

Clinical Trial Summary

Study CV-0003 will be the second clinical trial administering CV-MG01 in humans. This will be a phase 2/3 proof-of-efficacy therapeutic confirmatory study following the proof-of-concept exploratory phase 1 study (CV-0002).

Clinical Trial Description

The review of the clinical data accumulated so far in Study CV-0002 indicated that the safety and tolerability profile of CV-MG01 is considered very good, with positive immunogenicity results after the high dose regimen of CV-MG01. The preliminary results also show an indication of efficacy of CV-MG01, as based on the different scales and questionnaires results, all specific to MG disease. Therefore, it is proposed to investigate, in an appropriately designed, randomised, double-blind and powered study, the clinical efficacy of CV-MG01 in a larger cohort of MG patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03165435
Study type Interventional
Source CuraVac
Contact
Status Withdrawn
Phase Phase 2/Phase 3
Start date July 2018
Completion date December 31, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02565576 - Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis Phase 2
Completed NCT04115293 - Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Phase 3
Recruiting NCT05737160 - Study of Telitacicept in Generalized Myasthenia Gravis Phase 3
Recruiting NCT04224506 - A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
Recruiting NCT06455709 - Markers of Favorable Response to Complement Inhibitors Therapy
Recruiting NCT04431895 - Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study Early Phase 1
Recruiting NCT05067348 - Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis Phase 2
Recruiting NCT05214612 - Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Recruiting NCT05868837 - Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) Phase 3
Recruiting NCT06282159 - A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) Phase 2
Recruiting NCT04146051 - Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) Phase 2
Completed NCT03759366 - A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) Phase 3
Completed NCT02473952 - A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis Phase 2
Completed NCT00683969 - A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Phase 3
Completed NCT03304054 - Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Phase 3
Recruiting NCT05716035 - Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis Phase 2/Phase 3